|MDACC Study No:||2003-1002 (clinicaltrials.gov NCT No: NCT00500422)|
|Title:||Phase I Study of a Combination of Doxil, VELCADE, and Gemcitabine in Advanced Cancer|
|Principal Investigator:||Gerald Falchook|
|Treatment Agent:||Doxil; Gemcitabine; Velcade|
|Study Description:||The goal of this clinical research study is to find the highest safe dose of |
the drug Velcade (bortezomib) that can be given together with gemcitabine and
pegylated liposomal doxorubicin (Doxil) in the treatment of advanced cancer.
The effect of this combination treatment on tumor growth will also be studied.